ARDT — Ardent Health Partners, LLC

Summary of Ardent Health's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Increased by 8.8% year-over-year to $1.58 billion; 11.7% growth excluding a one-time revenue adjustment.
• Adjusted EBITDA: Rose 46% to $143 million, with a margin expansion of 240 basis points to 9.1%. Year-to-date, adjusted EBITDA is up 30%.
• Admissions Growth: Total admissions grew 5.8% in Q3 and 6.7% year-to-date, significantly outpacing population growth in their markets.
• Cash Flow: Strong operating cash flow of $154 million, up from $90 million in Q3 2024. Total cash at quarter-end was $609 million, with total debt of $1.1 billion.
• Leverage: Lease-adjusted net leverage improved to 2.5x from 2.7x in the previous quarter.

2. Strategic Updates and Business Highlights

• IMPACT Program: Launched to optimize costs and strengthen margins, with expected annual benefits of over $40 million starting in 2026. Initiatives include contract renegotiations and staffing adjustments.
• Surgical Volumes: Total surgeries increased by 1.4% in Q3, reversing a decline seen earlier in the year.
• Market Positioning: Ardent's markets are growing 2x to 3x faster than the national average, supported by demographic trends and rising care complexity.

3. Forward Guidance and Outlook

• Revised EBITDA Guidance: Updated full-year adjusted EBITDA guidance to $530 million to $555 million due to persistent cost pressures, particularly in professional fees and payer denials.
• Revenue Guidance: Maintained at $6.2 billion to $6.45 billion, indicating a 6% growth at the midpoint.
• 2026 Outlook: While specific guidance for 2026 will be provided in February, management expressed confidence in strong demand and ongoing growth initiatives.

4. Bad News, Challenges, or Points of Concern

• Cost Pressures: Persistent increases in professional fees (11% in Q3) and rising payer denials have negatively impacted earnings pull-through.
• Payer Denials: Increased denial rates, particularly among managed care products, have created significant headwinds.
• Adjustments: A $43 million revenue reduction due to a change in accounting estimates and a $54 million increase in liability reserves related to adverse claims in New Mexico were noted as isolated issues but contributed to financial pressures.

5. Notable Q&A Insights

• Payer Denials: Management acknowledged that denial activity is widespread across managed care and is not limited to specific contracts. They are actively increasing appeals and legal actions to address this.
• Future Growth: Despite current challenges, management remains committed to growth initiatives, including outpatient development and strategic partnerships.
• Shareholder Value: Discussions around potential share repurchase programs are ongoing, but management emphasized a focus on optimizing shareholder value through various means.
• Professional Fees: The increase in professional fees was attributed to specific specialties, with expectations of moderation as contracts are renegotiated.

Overall, while Ardent Health demonstrated strong revenue growth and operational improvements, it faces significant challenges from rising costs and payer denials that have led to a cautious outlook for the remainder of 2025 and into 2026.